Check 35,000+ stocks against 26 valuation models and 37 quality factors

Sanai Health Industry Group Company Limited (1889) fair value: what the stock is really worth

As of Sep 22, 2026: fair value of Sanai Health Industry Group Company Limited HK$0.14, price HK$0.20, upside -29.4%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? No
Add to watchlist

Healthcare · HK · ISIN KYG7785S1075

SH Thin data Sep 24, 2026

Sanai Health Industry Group Company Limited

1889 · HK

Weak valuationQuality is weak on top of the rich price.

!Fair value HK$0.1376 · Overvalued (−29%)

!Quality 44/100

!Weak Growth (revenue 5y −6.7 %/yr)

!Loss-making · -25.7% net margin (TTM)

!Low debt · negative free cash flow

!Mixed vs. peers (4/10)

!Narrow moat 12/100

!Evidence only low, so the estimate is less certain

26 models, one by oneBear HK$0.0909 to bull HK$0.1728 Growth analysisrevenue history, year by year Quality 44/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Sanai Health Industry Group Company Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range HK$0.1330 – HK$6.38 · fair‑value band HK$0.0909 – HK$0.1728 · the HK$0.1950 price screens above the HK$0.1376 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Sanai Health Industry Group Company in your weekly email

Every Wednesday you see whether Sanai Health Industry Group Company is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sanai Health Industry Group Company Limited, an investment holding company, engages in the manufacture, marketing, and sale of branded prescription and non-prescription drugs, and Chinese pharmaceutical products in the People's Republic of China and Hong Kong. It operates through Pharmaceutical Products and Finance Leasing segments. The company is involved in development, manufacturing, marketing, and sales of pharmaceutical products; sale of pharmaceutical related software; and provision of consultancy services. It also provides finance leasing services; and engages in the research, production, and sale of health products, functional foods, and skincare products in the field of soft capsule dosage form. Sanai Health Industry Group Company Limited was incorporated in 2006 and is based in Kwun Tong, Hong Kong.

Stock analysis

Sanai Health Industry Group Company Limited (1889) currently trades at HK$0.1950, while our model-based Fair Value estimate is HK$0.1376, implying the stock looks roughly 41.7% overvalued today.

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: HK$0.0909 (bear) to HK$0.1728 (bull), the price of HK$0.1950 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

Sanai Health Industry Group Company Limited reported revenue of 85.9M CNY in FY2025 versus 67.6M CNY in FY2021, a compound +6.2%/yr. Reported net income was −22.0M CNY in FY2025.

Key figures

Market cap HK$29.8M (≈ $3.8M) · P/S ratio 0.28 · EPS (TTM) HK$−0.0700 · Net margin −25.7% · Return on equity −7.9% · Return on assets (EBIT) 4.1% · Operating margin −28.7% · Revenue (TTM) HK$85.9M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).

What moves the price

The share trades about 71% below its 52-week high and 25% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −29%, 1889 screens richer than that median.

Fair Value models

Bear HK$0.0909 Fair Value HK$0.1376 Bull HK$0.1728

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

NCAV (Graham) HK$0.9800 HK$1.31 HK$1.95 54

All 1 models by family

Asset-Based

NCAV (Graham) HK$0.9800 HK$1.31 HK$1.95 54

Open the full fair value analysis →

Notify me when 1889 reaches fair value

Put 1889 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 44/100

Of which business quality 46 · Market factors (momentum, volatility) 20

Profitability 2

Margins and returns on capital today

Quality Growth 40

Are margins and returns improving?

Cashflow 33

Earnings quality: real cash, not paper profit

Fin. Strength 83

Balance sheet, leverage, solvency risk

Investment 84

Disciplined investing over empire-building

Low Volatility 50

Calm price path (market factor)

Momentum 10

Price trend over the last 3–12 months (market factor)

52W Momentum 4

Distance to the 52-week high (market factor)

Net Issuance 49

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 6/100

Revenue growth is weak: less than 2 % a year.

Revenue growth 1 year

+0.8%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−21.3%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−6.7%

Start year 2020 (pandemic). Over 10 years: −17.0% a year

Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−4.1%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

13.7% (2020) → −28.1% (2025)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

1889 screens 42% overvalued. Compare with Merck KGaA →

Compare Sanai Health Industry Group Company Limited with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 614 stocks

Beats the industry median on 4/9 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 46 · Below median

Fair Value upside −29% · Below median

Profitability

Return on assets −3% · Bottom 25%

Net margin (TTM) −26% · Bottom 25%

Operating margin (TTM) −29% · Bottom 25%

Growth and dividend

Revenue growth 29% · Top 25%

Balance sheet

Debt / equity 0.01× · Lowest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/S (TTM) 0.04× · Cheapest 25%

PEG 1.07× · Cheaper than median

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 12

FUTURE (revenue growth)100 · sector 21

PAST (return on equity)0 · sector 25

HEALTH (low debt)100 · sector 96

DIVIDEND (yield)0 · sector 30

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Merck KGaA MRK	€133.15	€108.70	−18%
Takeda Pharmaceutical Company TAK	$18.95	$11.29	−40%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥45.72	¥50.29	+10%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,846	₹1,979	+7%
Galderma Group GALD	CHF 163.80	CHF 109.88	−33%
Haleon plc HLN	$9.25	$8.50	−8%
Teva Pharmaceutical Industries Limited TEVA	$39.52	$20.75	−47%
Sandoz Group SDZ	CHF 70.76	CHF 40.16	−43%
Zoetis Inc ZTS	$72.86	$108.48	+49%
Hansoh Pharmaceutical Group 3692	HK$35.34	HK$38.87	+10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sanai Health Industry Group Company Limited · Fair Value
HK$0.1376 −42%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/1889" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Sanai Health Industry Group Company Limited · Fair Value</span><br><b style="font-size:20px">HK$0.1376</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−42%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Sanai Health Industry Group Company Limited Fair Value". https://www.fairvalue-calculator.com/stock/1889

Frequently asked questions

Is Sanai Health Industry Group Company Limited (1889) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of HK$0.1376 versus a price of HK$0.1950, about −29% upside (overvalued).

What is the fair value of 1889?

Our model-based fair value for Sanai Health Industry Group Company Limited is HK$0.1376 (as of Sep 24, 2026), built from audited fundamentals. The current price: HK$0.1950.

What is the quality score of 1889?

Sanai Health Industry Group Company Limited has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Sanai Health Industry Group Company Limited (1889)?

Our model-based price target is the fair value of HK$0.1376 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario HK$0.0909, optimistic scenario HK$0.1728. It is a calculation from audited fundamentals, not an analyst target.

What is the Sanai Health Industry Group Company Limited stock forecast for 2026?

Our models put fair value at HK$0.1376, about −29% upside versus a price of HK$0.1950 (overvalued). Cautious scenario HK$0.0909, optimistic scenario HK$0.1728. The calculation is refreshed regularly with new filings.

What is the revenue of Sanai Health Industry Group Company Limited (1889)?

Sanai Health Industry Group Company Limited reported trailing-twelve-month revenue of about HK$85.9M (latest available figure, as of Sep 24, 2026).

What is the intrinsic value of Sanai Health Industry Group Company Limited (1889)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sanai Health Industry Group Company Limited it is HK$0.1376 per share (as of Sep 24, 2026), against a price of HK$0.1950. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).

Is Sanai Health Industry Group Company Limited stock overvalued or undervalued in 2026?

As of Sep 24, 2026, 1889 trades above its calculated fair value: price HK$0.1950, fair value HK$0.1376, a gap of about −29% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 1889?

No. The price is what the market pays today (HK$0.1950); the fair value is what the company's own numbers justify (HK$0.1376). For Sanai Health Industry Group Company Limited the two are HK$0.0574 per share apart. That gap is exactly why we show both numbers side by side.

How much is Sanai Health Industry Group Company Limited worth?

The market values Sanai Health Industry Group Company Limited at about HK$29.8M (market capitalisation, as of Sep 24, 2026). Per share that is HK$0.1950; our models calculate a fair value of HK$0.1376 per share.

What do the bullish and bearish scenarios say about 1889?

Our models span a range for Sanai Health Industry Group Company Limited: cautious scenario HK$0.0909, base HK$0.1376, optimistic HK$0.1728 per share (as of Sep 24, 2026, price HK$0.1950). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the PEG ratio of 1889?

The PEG ratio of Sanai Health Industry Group Company Limited is 1.07 (P/E divided by earnings growth, as of Sep 24, 2026). That is above 1, so the growth is already paid for in the price.

How solid is the balance sheet of Sanai Health Industry Group Company Limited (1889)?

Balance-sheet figures for Sanai Health Industry Group Company Limited (as of Sep 24, 2026): return on equity −7.9%, debt of 0.01 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.

How far is 1889 from its 52-week high?

Sanai Health Industry Group Company Limited trades at HK$0.1950, about 71% below its 52-week high of HK$0.6700 and 25% above the low of HK$0.1560 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.1376 is for.

Which stocks are comparable to Sanai Health Industry Group Company Limited?

From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Sanai Health Industry Group Company Limited stock attractive at the current price?

The data as of Sep 24, 2026: price HK$0.1950, calculated fair value HK$0.1376 (−29%), Quality Score 44/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 1889 calculated?

We run Sanai Health Industry Group Company Limited through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$0.1376, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.1 % above its aggregate fair value. Sanai Health Industry Group Company Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Sanai Health Industry Group Company Limited (1889)?

The closing price on Sep 22, 2026 was HK$0.1950. Our model-based fair value is HK$0.1376, about −29% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Sanai Health Industry Group Company Limited right now?

The price sits above even our optimistic bull case (HK$0.1728). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (HK$0.0909 to HK$0.1728) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Sanai Health Industry Group Company Limited

How large is the market capitalisation of Sanai Health Industry Group Company Limited (1889)?

The market capitalisation of Sanai Health Industry Group Company Limited is HK$29.8M (≈ $3.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Sanai Health Industry Group Company Limited (1889)?

The price-to-sales ratio of Sanai Health Industry Group Company Limited is 0.28 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Sanai Health Industry Group Company Limited (1889)?

Earnings per share at Sanai Health Industry Group Company Limited are HK$−0.0700. Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Sanai Health Industry Group Company Limited (1889)?

The net margin of Sanai Health Industry Group Company Limited is −25.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Sanai Health Industry Group Company Limited (1889)?

The return on equity (ROE) of Sanai Health Industry Group Company Limited is −7.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Sanai Health Industry Group Company Limited (1889)?

On an EBIT basis the return on assets of Sanai Health Industry Group Company Limited is 4.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Sanai Health Industry Group Company Limited (1889)?

The operating margin of Sanai Health Industry Group Company Limited is −28.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Sanai Health Industry Group Company Limited (1889)?

Revenue at Sanai Health Industry Group Company Limited is growing +28.6% versus a year earlier (3y avg −21.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Sanai Health Industry Group Company Limited (1889)?

Earnings per share at Sanai Health Industry Group Company Limited are growing −39.6% versus a year earlier. How much earnings per share grew versus a year earlier.

How much free cash flow does Sanai Health Industry Group Company Limited (1889) generate?

The free cash flow of Sanai Health Industry Group Company Limited is −HK$54.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

Free · no account needed

Watch Sanai Health Industry Group Company Limited in the live analysis

One click puts Sanai Health Industry Group Company Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.